Clinical Trials Logo

Acute Pancreatitis clinical trials

View clinical trials related to Acute Pancreatitis.

Filter by:

NCT ID: NCT02743364 Completed - Acute Pancreatitis Clinical Trials

Simvastatin in Reducing Pancreatitis in Patients With Recurrent, Acute or Chronic Pancreatitis

Start date: September 19, 2016
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well simvastatin works in reducing pancreatitis (the inflammation of the pancreas) in patients with pancreatitis that occurs more than once (recurrent), has worsened quickly (acute), or has persisted or progressed over a long period of time (chronic). Simvastatin may decrease the inflammation of the pancreas by modulating the immune response responsible for inflammation. It is not yet known if simvastatin may be an effective treatment for pancreatitis.

NCT ID: NCT02692391 Completed - Acute Pancreatitis Clinical Trials

A Randomized Controlled Pilot Trial of Indomethacin in Acute Pancreatitis

Start date: July 2013
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind, placebo-controlled pilot trial seeking to evaluate the efficacy of rectal indomethacin in abrogating systemic inflammation and subsequently organ failure and mortality in patients with AP and positive SIRS score.

NCT ID: NCT02622854 Completed - Acute Pancreatitis Clinical Trials

Plasma Exchange vs Conservative Management in Non-severe Acute Hypertriglyceridemic Pancreatitis

Start date: June 2016
Phase: N/A
Study type: Interventional

To compare effectiveness in reducing triglycerides between daily plasma exchange and glucose+insulin infusion in patients with non-severe acute hypertriglyceridemic pancreatitis with mildly elevated triglycerides

NCT ID: NCT02602808 Completed - Acute Pancreatitis Clinical Trials

Study of Peripheral Blood Non-coding RNAs as Diagnosis and Prognosis Biomarker for Acute Pancreatitis

NCRNAP
Start date: December 2015
Phase:
Study type: Observational

It is important to identify patients with acute pancreatitis who are at risk for developing persistent organ failure early in the course of disease. The investigators evaluated whether peripheral blood non-coding RNAs, including microRNAs and long noncoding RNA (lncRNA), could serve as a good marker for detection of acute pancreatitis with persistent organ failure at early phase.

NCT ID: NCT02563080 Completed - Acute Pancreatitis Clinical Trials

Pancreatic Exocrine Insufficiency in Acute Pancreatitis

APPEI
Start date: September 2015
Phase:
Study type: Observational [Patient Registry]

Severe pancreatitis induces more damage in the pancreas and might therefore result reduced exocrine function leading to the insufficiency. The aim of this prospective study is to investigate development of pancreatic exocrine insufficiency in patients recovering from first attack of moderately severe or severe acute pancreatitis.

NCT ID: NCT02543658 Completed - Acute Pancreatitis Clinical Trials

Neostigmine Treatment of Acute Pancreatitis Combined With Intra-abdominal Hypertension

Start date: September 1, 2015
Phase: Phase 2
Study type: Interventional

Acute pancreatitis(A) often complicated with Intra-abdominal Hypertension. After the onset of acute pancreatitis, capillary leakage causing ascites,upper gastrointestinal tract obstruction and paralytic ileus leading to an elevated IAP, severe IAH leads to ACS with high mortality. Neostigmine is an anti-cholinesterase drugs, can enhance intestinal peristalsis, promote flatus defecation. The aim of this study was to determine the effect of neostigmine on reducing abdominal pressure and clinical prognosis in patients with AP by promoting intestinal peristalsis and defecation.

NCT ID: NCT02318134 Completed - Acute Pancreatitis Clinical Trials

Fecal Microbiota Transplantation for Pancreatitis

FMTP
Start date: November 18, 2017
Phase: Phase 2
Study type: Interventional

The intestinal microbiota plays a pivotal role in the maintenance of intestinal homeostasis and protecting the gut against pathogens by competing for nutrients, creating the intestinal biological barrier and modulating the host immune system.After the onset of acute pancreatitis,the intestinal hypoperfusion and the release of inflammatory mediators result in intestinal barrier dysfunction and intestinal bacteria dysbiosis.This leads to Bacterial and endotoxin translocation, which may cause infectious complications which are major causes of death in SAP patients.Recently,FMT was shown its efficacy in the treatment of gastrointestinal(GI) diseases and non-GI disorders associated with Intestinal flora disturbance by re-establishing the damaged Intestinal Bacteria homeostasis.However,the mechanism by which FMT results in cure of diseases has been poorly understood.This study aims to investigate the therapeutic potential of FMT for SAP patients with intestinal barrier dysfunction.

NCT ID: NCT02212392 Completed - Acute Pancreatitis Clinical Trials

Comparing the Outcome in Patients of Acute Pancreatitis, With and Without Prophylactic Antibiotics

Start date: January 2013
Phase: Phase 1/Phase 2
Study type: Interventional

The use of prophylactic antibiotics is beneficial in reducing the extrapancreatic infections and shorter hospital stay in patients of acute pancreatitis as compared to controls.

NCT ID: NCT02111707 Completed - Acute Pancreatitis Clinical Trials

Timing of Indomethacin Administration for the Prevention of Post-ERCP Pancreatitis (PEP)

Start date: April 2014
Phase: Phase 4
Study type: Interventional

To determine if the timing of administration of indomethacin affects the primary outcome of post-ERCP pancreatitis (PEP). Patients undergoing ERCP will be randomly assigned to receive pre or post-procedure rectal indomethacin to prevent the occurrence of PEP.

NCT ID: NCT01977118 Completed - Acute Pancreatitis Clinical Trials

Use of Streptokinase for Enhancement of Percutaneous Drainage of Pancreatic Necrosis

Start date: May 2013
Phase: Phase 2/Phase 3
Study type: Interventional

Around 20 per cent of patients with acute pancreatitis develop pancreatic or peripancreatic necrosis with or without peripancreatic collection. Percutaneous catheter drainage successfully drains the liquefied component of pancreatic necrosis while the solid component still remains undrained. This infected solid component of pancreatic necrosis is probably responsible for failure of percutaneous catheter drainage which demands surgical debridement. Streptokinase is a protein secreted by several species of streptococci which can bind and activate human plasminogen. In the present study investigators plan to instill streptokinase locally in to the collections of patients with severe acute pancreatitis via pigtail catheter inorder to liquefy the solid necrotic component and analyze whether it hastens the drainage and thereby delays or obviates the need for necrosectomy.